All In MedTech

Device Trial Radar · NCT04084041

Efficacy of Simeox Airway Clearance Therapy in Children With Cystic Fibrosis

Efficacy of the Simeox Airway Clearance Technology in the Treatment of Children With Clinically Stable Cystic Fibrosis- Cross-over Study With Randomization

Last checked: Nov 20, 2026Latest source record: Sep 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

40

Actual

Start

Sep 10, 2019

Primary completion

Jan 31, 2021

Study completion Feb 15, 2021

Sponsor

Lead sponsor
Physio-AssistNot on our public-company list
Sponsor type
Industry
First posted
Sep 10, 2019

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Crossover
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 8 years, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Chest physiotherapy plays a crucial role in treatment of lung disease in cystic fibrosis (CF). New airway clearance techniques (ACTs) adapted to individual needs are still being sought to achieve the best effect of airway clearance. The primary aim of this study is to assess the efficacy of a new ACT (Simeox) on pulmonary function in children with CF. 40 CF patients with stable respiratory function will be randomized 1:1 to Simeox or conventional chest physiotherapy (CCPT) therapy (control group) and treated at home during 1 month. After a short washout period, patients will be treated at home onto the alternative treatment for 1 month (crossover design). Lung function, quality of life, pulmonary exacerbation and safety will be evaluated at 1 month for each therapy period.

Conditions

  • Cystic Fibrosis in Children
  • Airway Clearance Impairment

Interventions

  • SimeoxDevice

    Airway clearance device

  • CCPTOther

    Conventional chest physiotherapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in total lung resistanceTime frame: 1 month

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • IMiD

    Warsaw, Poland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.